ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2022 investor letter. A copy of the same can be downloaded here. The second quarter was difficult for growth funds, and the fund underperformed the benchmark index. Only the consumer staples sector contributed positively to the fund’s performance. To know about the fund’s best picks in 2022, please check its top 5 holdings.
In the letter, ClearBridge Investments discussed its ClearBridge Large Cap Growth Strategy portfolio. The fund exited BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company, headquartered in San Rafael, California. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) closed at $95.82 per share on August 5, 2022. One-month return of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rose to 7.64% and its shares gained 22.64% of their value over the last 52 weeks. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has a market capitalization of $ 17.772billion.
Here is what ClearBridge Large Cap Growth Strategy specifically said about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in its second-quarter investor letter:
“Another sale during the quarter was BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), motivated by more attractive risk/reward opportunities elsewhere in the sector. We bought BioMarin in early 2018 after the launch of Vimizim (for Morquio syndrome) which made the company cash flow positive with a clear strategy for continued growth in orphan diseases. In late 2020, the FDA moved the goalpost from one to two years of data to approve BioMarin’s drug Valrox (Hemophilia A). However, the shares derated in late 2021 due to concerns around execution and commercial uptake as well as management issues. Given the opportunity cost of waiting for a takeout or an activist investor and thin remaining pipeline, we exited the position and redeployed the proceeds into higher growth areas in health care (i.e. diabetes, robotics, orthopedics). We continue to look for organic growers in the sector since health care should be less exposed to some of the inflationary pressures we see in other industries.”
Pressmaster/Shutterstock.com
Our research shows that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 56 hedge fund portfolios held BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at the end of the first quarter which was 48 in the previous quarter.
We discussed BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in another article and shared the top healthcare stocks to buy as per Michel Massoud’s Melqart Asset Management. In addition, please check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other leading investors.
Disclosure: None. This article is originally published at Insider Monkey.
When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.
Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.
At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.
Do the math. According to Musk, this technology could be worth $250 trillion by 2040.
Put another way, that’s roughly equal to:
175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias
And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.
It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.
Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.
How could anything be worth that much?
The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.
And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.
What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.
In fact, Verge argues this company’s supercheap AI technology should concern rivals.
Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.
Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.
When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.
Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…
But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.
And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…
This prediction might not be bold at all:
A few years from now, you’ll wish you’d owned this stock.
The best part? You can discover everything about this company and its groundbreaking technology right now.
I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.
Trust me — you’ll want to read this report before putting another dollar into any tech stock.
For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!
Here’s why this is a deal you can’t afford to pass up:
• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
• Bonus Reports: Premium access to members-only fund manager video interviews
• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.
If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.
Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.
Here’s what to do next:
1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.
2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!
